Biotech entity
Of the tracked stories, 2 of 3 also mention Department of Justice, the most common co-covered peer. Each story carries 13 original sources on average, compared with 3.4 for the broader beat in this window. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder.
Last mentioned: Mar 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention Department of Justice, the most common co-covered peer. Each story carries 13 original sources on average, compared with 3.4 for the broader beat in this window. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. That works out to roughly 0.2 stories per week across a 117-day span. The 7 average consequence score is above the beat benchmark of 6.2 in the same window. Centers for Medicare & Medicaid Services appears in 3 tracked Biotech stories published from March 4, 2026 through June 28, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 372 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Centers for Medicare & Medicaid Services. Shared-story counts are live from our verified record — not editorial picks.
Initial Expiration
The first six-month period ends, at which point CMS may choose to extend the moratorium.
Q4 2025 Earnings
Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
Moratorium Effective
CMS officially publishes the notice and the nationwide enrollment freeze begins immediately.
FDA 510(k) Submission
Premarket notification submitted for Lucent AD Complete diagnostic test.
CMS Reimbursement Milestone
CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.
Data Review Concludes
CMS finishes a multi-year review of Medicare enrollment and claims data identifying high-risk trends.
OIG Fraud Warning
HHS OIG highlights billions in improper DME payments over the previous decade.
Assay Portfolio Expansion
Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.
The DOJ’s operation specifically targeted fraudulent genetic testing schemes, sending shockwaves through biotech and pharma reliant on lab services. A new Data Fusion Center and $48.6M in settlements signal aggressive federal interest in precision medicine marketing.
Source: wercfm.iheart.com · knst.iheart.com
The Centers for Medicare & Medicaid Services (CMS) has implemented a six-month nationwide freeze on new Medicare enrollments for seven categories of medical supply companies. This aggressive regulatory move, effective February 27, 2026, aims to curb systemic fraud and billions in improper payments within the DMEPOS sector.
Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
Centers for Medicare & Medicaid Services is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
